RxDoctor Payments Data

Candice Bittinger

Family · Fredericksburg, VANPI 1962857300

Payments from drug & device makers

$6,557in general payments, 2019–2025

Across 313 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$834
  • GSK$433
  • Pfizer$376
  • Johnson & Johnson$333
  • Gilead$318
  • AstraZeneca$294
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$6,48799%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis46$834
GSK24$433
Pfizer18$376
Johnson & Johnson(2 entities)19$333
Gilead(2 entities)8$318
AstraZeneca(2 entities)12$294
Daiichi Sankyo Inc.19$281
Merck13$261
Incyte Corporation9$220
Seagen Inc.6$175
Bayer8$174
E.r. Squibb & Sons, L.L.C.6$149
Eisai Inc.6$145
AbbVie6$134
Ipsen Biopharmaceuticals, Inc6$130
Sanofi4$119
Beone Medicines USA, Inc.5$118
Taiho Oncology, Inc.4$102
Puma Biotechnology, Inc.6$95
EMD Serono, Inc.4$94
Amgen4$92
Beigene USA, Inc.5$89
Dendreon Pharmaceuticals LLC4$88
Pharmacyclics LLC, An Abbvie Company4$83
Pharmaessentia USA Corporation3$82
Servier Pharmaceuticals LLC4$76
Adaptive Biotechnologies Corporation3$71
Astellas Pharma US Inc4$70
Lilly USA, LLC4$67
GE HealthCare2$67
Genentech USA, Inc.3$61
Accord Healthcare, Inc.3$57
Karyopharm Therapeutics Inc.2$56
Tersera Therapeutics LLC2$56
Mirati Therapeutics, Inc.2$55
Pharmacosmos Therapeutics Inc.3$52
Blue Earth Diagnostics2$50
Menarini Silicon Biosystems, Inc.2$50
ADC Therapeutics America, Inc.3$48
Blueprint Medicines Corporation2$44
Legend Biotech USA Inc.2$44
Jazz Pharmaceuticals Inc.2$44
Sobi, Inc2$43
Array Biopharma Inc2$35
Coherus Oncology, Inc.1$31
Tempus AI, Inc1$30
G1 Therapeutics, Inc.1$25
Spectrum Pharmaceuticals Inc.1$23
Regeneron Healthcare Solutions, Inc.1$22
Bristol Myers Squibb1$20
Alnylam Pharmaceuticals Inc.1$20
Myriad Genetic Laboratories, Inc.1$17
Acrotech Biopharma Inc.1$16
Agios Pharmaceuticals, Inc.1$16
Progenics Pharmaceuticals, Inc.1$16
Morphosys, US Inc.1$16
Tactile Systems Technology Inc1$15
Recordati_rare_diseases_inc.1$15
Acceleron Pharma, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,557 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$16,302
Medicare patients
127
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib16$148,772
Ondansetron Hcl21$668
Prochlorperazine Maleate17$254
Oxycodone Hcl12$141
Prednisone11$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$294$148,77216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →